498537-27-2

Basic information

• Product Name: 2-{[5-(4-aminophenyl)-4-methyl-4H-1,2,4-triazol-3-yl]sulfanyl}-N-(2-{[2-(benzylamino)-2-oxoethyl]sulfanyl}-1,3-benzothiazol-6-yl)acetamide
• Synonyms: 2-{[5-(4-aminophenyl)-4-methyl-4H-1,2,4-triazol-3-yl]sulfanyl}-N-(2-{[2-(benzylamino)-2-oxoethyl]sulfanyl}-1,3-benzothiazol-6-yl)acetamide
• CAS NO: 498537-27-2
• Molecular Formula: C₂₇H₂₅N₇O₂S₃
• Molecular Weight: 575.7281
• Mol File: 498537-27-2.mol
• Article Data: 1

Chemical Properties

• Appearance: /
• CAS DataBase Reference: 2-{[5-(4-aminophenyl)-4-methyl-4H-1,2,4-triazol-3-yl]sulfanyl}-N-(2-{[2-(benzylamino)-2-oxoethyl]sulfanyl}-1,3-benzothiazol-6-yl)acetamide(CAS DataBase Reference)
• NIST Chemistry Reference: 2-{[5-(4-aminophenyl)-4-methyl-4H-1,2,4-triazol-3-yl]sulfanyl}-N-(2-{[2-(benzylamino)-2-oxoethyl]sulfanyl}-1,3-benzothiazol-6-yl)acetamide(498537-27-2)
• EPA Substance Registry System: 2-{[5-(4-aminophenyl)-4-methyl-4H-1,2,4-triazol-3-yl]sulfanyl}-N-(2-{[2-(benzylamino)-2-oxoethyl]sulfanyl}-1,3-benzothiazol-6-yl)acetamide(498537-27-2)

Safety Data

• Hazardous Substances Data: 498537-27-2(Hazardous Substances Data)

Upstream product

• 5351-17-7 4-aminobenzohydrazide 
• 619-45-4 4-methoxycarbonyl aniline 
• 150-13-0 4-amino-benzoic acid 
• 100-46-9 benzylamine 
• 7442-07-1 6-aminobenzo[d]thiazole-2(3H)-thione 
• 884238-41-9 C₁₆H₁₅N₃OS₂ 
• 149622-77-5 5-(4-aminophenyl)-2,4-dihydro-4-methyl-3H-1,2,4-triazole-3-thione 
• 2945-03-1 N-benzyl-2-bromoacetamide 
• 4845-58-3 6-nitrobenzo[d]thiazole-2(3H)-thione 
• 149-30-4 2-thioxo-3H-1,3-benzothiazole 
• 137-07-5 2-amino-benzenethiol 
• 827579-80-6 2-(4-aminobenzoyl)-N-methylhydrazinecarbothioamide 

Relevant articles and documents

Synthesis and invitro Evaluation of West Nile Virus Protease Inhibitors Based on the 2-{6-[2-(5-Phenyl-4H-{1,2,4]triazol-3-ylsulfanyl)acetylamino]benzothiazol-2-ylsulfanyl}acetamide Scaffold

In recent years, clinical symptoms resulting from West Nile virus (WNV) infection have worsened in severity, with an increased frequency in neuroinvasive diseases among the elderly. As there are presently no successful therapies against WNV for use in humans, continual efforts to develop new chemotherapeutics against this virus are highly desired. The viral NS2B-NS3 protease is a promising target for viral inhibition due to its importance in viral replication and its unique substrate preference. In this study, a WNV NS2B-NS3 protease inhibitor with a 2-{6-[2-(5-phenyl-4H-[1,2,4]triazol-3-ylsulfanyl)acetylamino]benzothiazol-2-ylsulfanyl}acetamide scaffold was identified during screening. Optimization of this initial hit by synthesis and screening of a focused compound library with this scaffold led to the identification of a novel uncompetitive inhibitor (1a24, IC50=3.4±0.2μM) of the WNV NS2B-NS3 protease. Molecular docking of 1a24 into the WNV protease showed that the compound interferes with productive interactions of the NS2B cofactor with the NS3 protease and is an allosteric inhibitor of the WNV NS3 protease.